{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:52:13Z","timestamp":1793976733324,"version":"4.8.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["XDB38010100"],"award-info":[{"award-number":["XDB38010100"]}],"id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070464"],"award-info":[{"award-number":["82070464"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370444"],"award-info":[{"award-number":["82370444"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFC2500500"],"award-info":[{"award-number":["2021YFC2500500"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017668","name":"Anhui Provincial Key Research and Development Plan","doi-asserted-by":"publisher","award":["202104j07020051"],"award-info":[{"award-number":["202104j07020051"]}],"id":[{"id":"10.13039\/501100017668","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005156","name":"Alexander von Humboldt-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003995","name":"Natural Science Foundation of Anhui Province","doi-asserted-by":"publisher","award":["2208085J08"],"award-info":[{"award-number":["2208085J08"]}],"id":[{"id":"10.13039\/501100003995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.drudis.2024.103910","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T12:49:46Z","timestamp":1706791786000},"page":"103910","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":220,"title":["NAFLD and NASH: etiology, targets and emerging therapies"],"prefix":"10.1016","volume":"29","author":[{"given":"Shulin","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suowen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2024.103910_b0005","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"177","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2024.103910_b0010","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2024.103910_b0015","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jhep.2023.03.038","article-title":"An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH","volume":"79","author":"Tacke","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2024.103910_b0020","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","article-title":"Changing epidemiology, global trends and implications for outcomes of NAFLD","volume":"79","author":"Wong","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2024.103910_b0025","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S2468-1253(22)00317-X","article-title":"Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis","volume":"8","author":"Quek","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.drudis.2024.103910_b0030","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.mayocp.2015.06.013","article-title":"Recommendations for diagnosis, referral for liver biopsy, and treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"90","author":"Spengler","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.drudis.2024.103910_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2023.101133","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"29","author":"Rinella","year":"2024","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.drudis.2024.103910_b0040","article-title":"Can we use old NAFLD data under the new MASLD definition?","author":"Song","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2024.103910_b0045","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S2468-1253(23)00159-0","article-title":"NASH drug treatment development: challenges and lessons","volume":"8","author":"Tilg","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.drudis.2024.103910_b0050","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1053\/j.gastro.2008.01.075","article-title":"Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects","volume":"135","author":"Korenblat","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drudis.2024.103910_b0055","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.cmet.2023.08.002","article-title":"Resistant starch decreases intrahepatic triglycerides in patients with NAFLD via gut microbiome alterations","volume":"35","author":"Ni","year":"2023","journal-title":"Cell Metab"},{"key":"10.1016\/j.drudis.2024.103910_b0060","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa2114833","article-title":"Calorie restriction with or without time-restricted eating in weight loss","volume":"386","author":"Liu","year":"2022","journal-title":"New Engl J Med"},{"key":"10.1016\/j.drudis.2024.103910_b0065","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/s41467-023-35861-1","article-title":"Western diet contributes to the pathogenesis of non-alcoholic steatohepatitis in male mice via remodeling gut microbiota and increasing production of 2-oleoylglycerol","volume":"14","author":"Yang","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2024.103910_b0070","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.fshw.2022.10.026","article-title":"High-starchy carbohydrate diet aggravates NAFLD by increasing fatty acids influx mediated by NOX2","volume":"12","author":"Gao","year":"2023","journal-title":"Food Sci Hum Well"},{"key":"10.1016\/j.drudis.2024.103910_b0075","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/hep.32381","article-title":"Discovery of an insulin-induced gene binding compound that ameliorates nonalcoholic steatohepatitis by inhibiting sterol regulatory element-binding protein-mediated lipogenesis","volume":"76","author":"Jiang","year":"2022","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.drudis.2024.103910_b0080","article-title":"Cholesterol-associated locus EHBP1 protects against NASH fibrosis","author":"Ma","year":"2023","journal-title":"BioRxiv"},{"key":"10.1016\/j.drudis.2024.103910_b0085","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41586-022-05299-4","article-title":"Gut bacteria alleviate smoking-related NASH by degrading gut nicotine","volume":"610","author":"Chen","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2024.103910_b0090","article-title":"Potential therapeutic implications of histidine catabolism by the gut microbiota in NAFLD patients with morbid obesity","volume":"4","author":"Quesada-V\u00e1zquez","year":"2023","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.drudis.2024.103910_b0095","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1021\/acs.jafc.9b00080","article-title":"Intestinal barrier function-non-alcoholic fatty liver disease interactions and possible role of gut microbiota","volume":"67","author":"Cui","year":"2019","journal-title":"J Agri Food Chem"},{"key":"10.1016\/j.drudis.2024.103910_b0100","article-title":"Electronic health record-based genome-wide meta-analysis provides insights on the genetic architecture of non-alcoholic fatty liver disease","volume":"2","author":"Ghodsian","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.drudis.2024.103910_b0105","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/j.cmet.2023.10.008","article-title":"The PNPLA3 I148M variant increases ketogenesis and decreases hepatic de novo lipogenesis and mitochondrial function in humans","volume":"35","author":"Luukkonen","year":"2023","journal-title":"Cell Metab"},{"key":"10.1016\/j.drudis.2024.103910_b0110","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.jhep.2022.03.031","article-title":"Rare ATG7 genetic variants predispose patients to severe fatty liver disease","volume":"77","author":"Baselli","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2024.103910_b0115","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2217543120","article-title":"Inhibition of HSD17B13 protects against liver fibrosis by inhibition of pyrimidine catabolism in nonalcoholic steatohepatitis","volume":"120","author":"Luukkonen","year":"2023","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2024.103910_b0120","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.jhep.2023.06.019","article-title":"Downregulation of microRNA-145a-5p promotes steatosis-to-NASH progression through upregulation of Nr4a2","volume":"79","author":"Li","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2024.103910_b0125","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s43657-021-00023-0","article-title":"Causal relationship between complement C3, C4, and nonalcoholic fatty liver disease: bidirectional mendelian randomization analysis","volume":"1","author":"Li","year":"2021","journal-title":"Phenomics (Cham, Switzerland)"},{"key":"10.1016\/j.drudis.2024.103910_b0130","doi-asserted-by":"crossref","DOI":"10.1172\/JCI166149","article-title":"TRIM56 protects against non-alcoholic fatty liver disease via promoting the degradation of fatty acid synthase","author":"Xu","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2024.103910_b0135","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.jcmgh.2022.06.007","article-title":"Cell-specific deletion of NLRP3 inflammasome identifies myeloid cells as key drivers of liver inflammation and fibrosis in murine steatohepatitis","volume":"14","author":"Kaufmann","year":"2022","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.drudis.2024.103910_b0140","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1111\/liv.15610","article-title":"Protective role of cGAS in NASH is related to the maintenance of intestinal homeostasis","volume":"43","author":"de Carvalho Ribeiro","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.drudis.2024.103910_b0145","first-page":"6321","article-title":"Reactive oxygen species (ROS)-mediated oxidative stress in chronic liver diseases and its mitigation by medicinal plants","volume":"15","author":"Sharma","year":"2023","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.drudis.2024.103910_b0150","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.3390\/ijms21113858","article-title":"Relevance of SIRT1-NF-\u03baB axis as therapeutic target to ameliorate inflammation in liver disease","volume":"21","author":"de Gregorio","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2024.103910_b0155","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cmet.2019.10.014","article-title":"Neutralization of oxidized phospholipids ameliorates non-alcoholic steatohepatitis","volume":"31","author":"Sun","year":"2020","journal-title":"Cell Metab"},{"key":"10.1016\/j.drudis.2024.103910_b0160","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jhep.2021.01.042","article-title":"FOXA3 induction under endoplasmic reticulum stress contributes to non-alcoholic fatty liver disease","volume":"75","author":"Liu","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2024.103910_b0165","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s00125-016-3902-y","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"59","author":"European Association for the Study of the Liver","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.drudis.2024.103910_b0170","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/dom.12809","article-title":"Long-term effect of exercise on improving fatty liver and cardiovascular risk factors in obese adults: a 1-year follow-up study","volume":"19","author":"Zhang","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.drudis.2024.103910_b0175","doi-asserted-by":"crossref","first-page":"e233513","DOI":"10.1001\/jamanetworkopen.2023.3513","article-title":"Effects of time-restricted eating on nonalcoholic fatty liver disease: the TREATY-FLD randomized clinical trial","volume":"6","author":"Wei","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.drudis.2024.103910_b0180","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(23)00773-0","article-title":"Bariatric-metabolic surgery versus lifestyle intervention in non-alcoholic steatohepatitis","volume":"401","author":"Mahgoub","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2024.103910_b0185","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1007\/s11695-022-06011-1","article-title":"Bariatric surgery improves nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"32","author":"Zhou","year":"2022","journal-title":"Obes Surg"},{"key":"10.1016\/j.drudis.2024.103910_b0190","doi-asserted-by":"crossref","first-page":"e2235003","DOI":"10.1001\/jamanetworkopen.2022.35003","article-title":"Association of bariatric surgery with cardiovascular outcomes in adults with severe obesity and nonalcoholic fatty liver disease","volume":"35","author":"Elsaid","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.drudis.2024.103910_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106786","article-title":"Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD)","volume":"192","author":"Qiu","year":"2023","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.drudis.2024.103910_b0200","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-\u03b1\/\u03b3 agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial","volume":"74","author":"Gawrieh","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2024.103910_b0205","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"New Engl J Med"},{"key":"10.1016\/j.drudis.2024.103910_b0210","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/apt.16596","article-title":"Randomised clinical trial: pemafibrate, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1), versus placebo in patients with non-alcoholic fatty liver disease","volume":"54","author":"Nakajima","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.drudis.2024.103910_b0215","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1089\/thy.2018.0664","article-title":"Nonalcoholic fatty liver disease and hypercholesterolemia: roles of thyroid hormones, metabolites, and agonists","volume":"29","author":"Sinha","year":"2019","journal-title":"Thyroid"},{"key":"10.1016\/j.drudis.2024.103910_b0220","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/hep4.1657","article-title":"Effects of resmetirom on noninvasive endpoints in a 36-week phase 2 active treatment extension study in patients with NASH","volume":"5","author":"Harrison","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.drudis.2024.103910_b0225","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2024.103910_b0230","doi-asserted-by":"crossref","first-page":"13105","DOI":"10.3390\/ijms222313105","article-title":"TG68, a novel thyroid hormone receptor-\u03b2 agonist for the treatment of NAFLD","volume":"22","author":"Caddeo","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2024.103910_b0235","doi-asserted-by":"crossref","first-page":"66","DOI":"10.7150\/ijbs.73936","article-title":"Targeting FGF21 in cardiovascular and metabolic diseases: from mechanism to medicine","volume":"19","author":"Tan","year":"2023","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.drudis.2024.103910_b0240","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S2468-1253(22)00347-8","article-title":"Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b\/2a multiple-ascending-dose study","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.drudis.2024.103910_b0245","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"New Engl J Med"},{"key":"10.1016\/j.drudis.2024.103910_b0250","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2024.103910_b0255","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"8","author":"Harrison","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.drudis.2024.103910_b0260","doi-asserted-by":"crossref","first-page":"15338","DOI":"10.1096\/fj.202000836RR","article-title":"N-glycosylation of CREBH improves lipid metabolism and attenuates lipotoxicity in NAFLD by modulating PPAR\u03b1 and SCD-1","volume":"34","author":"Zhang","year":"2020","journal-title":"FASEB J"},{"key":"10.1016\/j.drudis.2024.103910_b0265","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41591-021-01495-3","article-title":"Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial","volume":"27","author":"Ratziu","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2024.103910_b0270","doi-asserted-by":"crossref","first-page":"e123294","DOI":"10.1172\/jci.insight.123294","article-title":"ASK1 inhibition reduces cell death and hepatic fibrosis in an Nlrp3 mutant liver injury model","volume":"5","author":"Schuster-Gaul","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.drudis.2024.103910_b0275","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials","volume":"73","author":"Harrison","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2024.103910_b0280","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/dom.14272","article-title":"Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non-alcoholic fatty liver disease: results from two early-phase randomized trials. Diabetes","volume":"23","author":"Beysen","year":"2021","journal-title":"Obes Metab"},{"key":"10.1016\/j.drudis.2024.103910_b0285","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1053\/j.gastro.2021.07.025","article-title":"TVB-2640 (FASN Inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled phase 2a trial","volume":"161","author":"Loomba","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drudis.2024.103910_b0290","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.clinthera.2022.12.008","article-title":"Inhibition of diacylglycerol acyltransferase 2 versus diacylglycerol acyltransferase 1: potential therapeutic implications of pharmacology","volume":"45","author":"Amin","year":"2023","journal-title":"Clin Ther"},{"key":"10.1016\/j.drudis.2024.103910_b0295","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.celrep.2018.12.036","article-title":"Genetic liver-specific AMPK activation protects against diet-induced obesity and NAFLD","volume":"26","author":"Garcia","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.drudis.2024.103910_b0300","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/1753-0407.12555","article-title":"Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease","volume":"9","author":"Feng","year":"2017","journal-title":"J Diabetes"},{"key":"10.1016\/j.drudis.2024.103910_b0305","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/hep4.1036","article-title":"Treating fatty liver disease by modulating mitochondrial pyruvate metabolism","volume":"1","author":"Colca","year":"2017","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.drudis.2024.103910_b0310","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jhep.2019.10.023","article-title":"Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase IIb study","volume":"72","author":"Harrison","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2024.103910_b0315","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.cmet.2021.06.012","article-title":"FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption","volume":"33","author":"Clifford","year":"2021","journal-title":"Cell Metab"},{"key":"10.1016\/j.drudis.2024.103910_b0320","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","article-title":"NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice","volume":"66","author":"Mridha","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2024.103910_b0325","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jhep.2021.10.029","article-title":"Non-invasive evaluation of response to obeticholic acid in patients with NASH: results from the REGENERATE study","volume":"76","author":"Rinella","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2024.103910_b0330","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12876-023-02653-2","article-title":"PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis","volume":"23","author":"Trauner","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.drudis.2024.103910_b0335","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41591-022-02200-8","article-title":"Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a\/b trial","volume":"29","author":"Sanyal","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2024.103910_b0340","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jhep.2021.10.018","article-title":"EDP-305 in patients with NASH: a phase II double-blind placebo-controlled dose-ranging study","volume":"76","author":"Ratziu","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2024.103910_b0345","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S2468-1253(22)00338-7","article-title":"Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease","volume":"8","author":"Targher","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.drudis.2024.103910_b0350","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"New Engl J Med"},{"key":"10.1016\/j.drudis.2024.103910_b0355","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1038\/s42255-023-00938-0","article-title":"Cotadutide promotes glycogenolysis in people with overweight or obesity diagnosed with type 2 diabetes","volume":"5","author":"Parker","year":"2023","journal-title":"Nat Metab"},{"key":"10.1016\/j.drudis.2024.103910_b0360","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jhep.2023.05.013","article-title":"A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease","volume":"79","author":"Romero-G\u00f3mez","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2024.103910_b0365","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41591-022-01707-4","article-title":"Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis","volume":"28","author":"Sattar","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2024.103910_b0370","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1111\/obr.12755","article-title":"Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms","volume":"19","author":"Lee","year":"2018","journal-title":"Obes Rev"},{"key":"10.1016\/j.drudis.2024.103910_b0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155657","article-title":"SGLT2 inhibitor empagliflozin downregulates miRNA-34a-5p and targets GREM2 to inactivate hepatic stellate cells and ameliorate non-alcoholic fatty liver disease-associated fibrosis","volume":"146","author":"Shen","year":"2023","journal-title":"Metab Clin Exp"},{"key":"10.1016\/j.drudis.2024.103910_b0380","doi-asserted-by":"crossref","first-page":"818","DOI":"10.3390\/ijms22020818","article-title":"Empagliflozin attenuates non-alcoholic fatty liver disease (NAFLD) in high fat diet fed ApoE((-\/-)) mice by activating autophagy and reducing ER stress and apoptosis","volume":"22","author":"Nasiri-Ansari","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2024.103910_b0385","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.drudis.2024.103910_b0390","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/jdi.12980","article-title":"Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease","volume":"10","author":"Inoue","year":"2019","journal-title":"J Diabetes Invest"},{"key":"10.1016\/j.drudis.2024.103910_b0395","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1515\/med-2018-0059","article-title":"Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease","volume":"13","author":"Miyake","year":"2018","journal-title":"Open Med"},{"key":"10.1016\/j.drudis.2024.103910_b0400","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.cmet.2022.05.004","article-title":"Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia","volume":"34","author":"Morrow","year":"2022","journal-title":"Cell Metab"},{"key":"10.1016\/j.drudis.2024.103910_b0405","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.apsb.2022.06.011","article-title":"Development of the novel ACLY inhibitor 326E as a promising treatment for hypercholesterolemia","volume":"13","author":"Xie","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.drudis.2024.103910_b0410","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jcmgh.2020.06.001","article-title":"Acetyl-CoA carboxylase inhibition improves multiple dimensions of NASH pathogenesis in model systems","volume":"10","author":"Ross","year":"2020","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.drudis.2024.103910_b0415","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.cgh.2018.04.042","article-title":"Acetyl-CoA carboxylase inhibitor GS-0976 for 12 weeks reduces hepatic de novo lipogenesis and steatosis in patients with nonalcoholic steatohepatitis","volume":"16","author":"Lawitz","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.drudis.2024.103910_b0420","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hep.31622","article-title":"Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2024.103910_b0425","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jhep.2022.04.003","article-title":"Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: a randomised, open-label phase II trial","volume":"77","author":"Alkhouri","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2024.103910_b0430","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/hep.32742","article-title":"Fibroblast growth factor receptor 1\/Klotho\u03b2 agonist BFKB8488A improves lipids and liver health markers in patients with diabetes or NAFLD: a phase 1b randomized trial","volume":"78","author":"Wong","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2024.103910_b0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108778","article-title":"Biological mechanisms and related natural modulators of liver X receptor in nonalcoholic fatty liver disease","volume":"113","author":"Ni","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.drudis.2024.103910_b0440","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/apt.13981","article-title":"Randomised clinical trial: the efficacy and safety of oltipraz, a liver X receptor alpha-inhibitory dithiolethione in patients with non-alcoholic fatty liver disease","volume":"45","author":"Kim","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.drudis.2024.103910_b0445","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cgh.2023.04.003","article-title":"Cenicriviroc lacked efficacy to treat liver fibrosis in nonalcoholic steatohepatitis: AURORA phase III randomized study","volume":"22","author":"Anstee","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.drudis.2024.103910_b0450","doi-asserted-by":"crossref","first-page":"7151","DOI":"10.1038\/s41467-023-42398-w","article-title":"A randomised Phase IIa trial of amine oxidase copper-containing 3 (AOC3) inhibitor BI 1467335 in adults with non-alcoholic steatohepatitis","volume":"14","author":"Newsome","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2024.103910_b0455","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.1038\/s41467-023-42162-0","article-title":"ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD, A randomized, placebo-controlled phase Ib\/IIa trial","volume":"14","author":"Hu","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2024.103910_b0460","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41587-023-01787-8","article-title":"NASH therapies head toward landmark approval","volume":"41","author":"Dolgin","year":"2023","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.drudis.2024.103910_b0465","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jhep.2022.11.025","article-title":"A phase I\/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis","volume":"78","author":"Mak","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2024.103910_b0470","article-title":"Two sides of the same coin: non-alcoholic fatty liver disease and atherosclerosis","volume":"154","author":"Zhu","year":"2023","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.drudis.2024.103910_b0475","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.jhep.2023.05.046","article-title":"Liver disease is a significant risk factor for cardiovascular outcomes \u2013 A UK Biobank study","volume":"79","author":"Roca-Fernandez","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2024.103910_b0480","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.jhep.2023.08.023","article-title":"Hepatic steatosis aggravates atherosclerosis via small extracellular vesicle-mediated inhibition of cellular cholesterol efflux","volume":"79","author":"Chen","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2024.103910_b0485","doi-asserted-by":"crossref","first-page":"eabp9435","DOI":"10.1126\/sciadv.abp9435","article-title":"Exosome-mediated delivery of Cas9 ribonucleoprotein complexes for tissue-specific gene therapy of liver diseases","volume":"8","author":"Wan","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.drudis.2024.103910_b0490","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.7150\/ijbs.65044","article-title":"Mouse models of nonalcoholic fatty liver disease (NAFLD): pathomechanisms and pharmacotherapies","volume":"18","author":"Fang","year":"2022","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.drudis.2024.103910_b0495","article-title":"A multicellular liver organoid model for investigating hepatitis C virus infection and non-alcoholic fatty liver disease progression","author":"Lee","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2024.103910_b0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101165","article-title":"Hepatocyte-targeted siTAZ therapy lowers liver fibrosis in NASH diet-fed chimeric mice with hepatocyte-humanized livers","volume":"31","author":"Wang","year":"2023","journal-title":"Mol Ther Methods Clin Dev"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644624000357?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644624000357?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T16:03:42Z","timestamp":1778601822000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644624000357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":100,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1359644624000357"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2024.103910","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NAFLD and NASH: etiology, targets and emerging therapies","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2024.103910","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103910"}}